Profusa, Inc. Common Stock (PFSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Profusa, Inc. Common Stock (PFSA) has a cash flow conversion efficiency ratio of 0.091x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.58 Million) by net assets ($-28.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PFSA cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Profusa, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Profusa, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Profusa, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Profusa, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Team Internet Group PLC
LSE:TIG
|
0.091x |
|
Taylor Maritime Investments Limited
LSE:TMIP
|
0.061x |
|
Awareness Group
NASDAQ:TAAG
|
0.160x |
|
Inspecs Group plc
LSE:SPEC
|
0.071x |
|
Amati AIM VCT plc
LSE:AMAT
|
-0.004x |
|
Tombador Iron Ltd
AU:TI1
|
-0.062x |
|
QVC Group Inc
NASDAQ:QVCGA
|
-0.001x |
|
Global Opportunities Trust Ord
LSE:GOT
|
N/A |
Annual Cash Flow Conversion Efficiency for Profusa, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Profusa, Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see PFSA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-26.66 Million | $-16.25 Million | 0.609x | +3416.71% |
| 2024-12-31 | $-119.20 Million | $-2.07 Million | 0.017x | -56.69% |
| 2023-12-31 | $-110.00 Million | $-4.40 Million | 0.040x | -48.16% |
| 2022-12-31 | $-99.77 Million | $-7.70 Million | 0.077x | -39.59% |
| 2021-12-31 | $-83.66 Million | $-10.69 Million | 0.128x | -- |
About Profusa, Inc. Common Stock
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platf… Read more